武田制药
TAK14.915USD
+0.085+0.57%
收盘 12/19, 16:00（美东）报价延迟15分钟
47.12B总市值
209.33市盈率 TTM
关于 武田制药 公司
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
武田制药简介
公司代码TAK
公司名称Takeda Pharmaceutical Co Ltd
上市日期Jun 21, 2085
CEOWeber (Christophe)
员工数量47455
证券类型Depository Receipt
年结日Jun 21
公司地址4F
城市CHUO-KU
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Japan
邮编103-8668
电话81332782111
网址https://www.takeda.com/
公司代码TAK
上市日期Jun 21, 2085
CEOWeber (Christophe)
武田制药公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
其他
62.70B
5.67%
地区USD
名称
营收
占比
United States
546.70B
49.40%
Europe And Canada (Country)
262.30B
23.70%
Japan
108.00B
9.76%
Latin America
57.60B
5.20%
China (Country)
43.20B
3.90%
其他
88.90B
8.03%
业务
地区
业务USD
名称
营收
占比
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
其他
62.70B
5.67%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
98.94%
持股股东
持股股东
占比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
98.94%
股东类型
持股股东
占比
Investment Advisor
1.85%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.31%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
其他
97.27%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital Research Global Investors
13.30M
0.42%
+94.57K
+0.72%
Jun 30, 2025
Parametric Portfolio Associates LLC
5.97M
0.19%
+676.71K
+12.78%
Jun 30, 2025
UBS Financial Services, Inc.
3.98M
0.13%
+2.28M
+133.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.08M
0.13%
+275.19K
+7.23%
Jun 30, 2025
Brandes Investment Partners, L.P.
3.71M
0.12%
+208.14K
+5.94%
Jun 30, 2025
Renaissance Technologies LLC
3.30M
0.1%
+141.50K
+4.48%
Jun 30, 2025
Goldman Sachs Asset Management, L.P.
2.85M
0.09%
-44.41K
-1.53%
Jun 30, 2025
Aperio Group, LLC
3.20M
0.1%
+574.34K
+21.83%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.22M
0.04%
-181.77K
-12.98%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
查看更多
VanEck Pharmaceutical ETF
占比5.05%
SGI Enhanced Global Income ETF
占比0.76%
Adasina Social Justice All Cap Global ETF
占比0.49%
First Trust Value Line Dividend Index Fund
占比0.38%
ActivePassive International Equity ETF
占比0.3%
Avantis Responsible International Equity ETF
占比0.09%
Avantis International Equity ETF
占比0.05%
Roundhill GLP-1 & Weight Loss ETF
占比0%
DFA Dimensional International Core Equity 2 ETF
占比0%
Invesco Zacks Multi-Asset Income ETF
占比0%
分红派息
近5年累计派现
1.44T
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
武田制药的前五大股东是谁？
武田制药 的前五大股东如下：
Capital Research Global Investors持有股份：13.30M，占总股份比例：0.42%。
Parametric Portfolio Associates LLC持有股份：5.97M，占总股份比例：0.19%。
UBS Financial Services, Inc.持有股份：3.98M，占总股份比例：0.13%。
Fidelity Management & Research Company LLC持有股份：4.08M，占总股份比例：0.13%。
Brandes Investment Partners, L.P.持有股份：3.71M，占总股份比例：0.12%。
Capital Research Global Investors持有股份：13.30M，占总股份比例：0.42%。
Parametric Portfolio Associates LLC持有股份：5.97M，占总股份比例：0.19%。
UBS Financial Services, Inc.持有股份：3.98M，占总股份比例：0.13%。
Fidelity Management & Research Company LLC持有股份：4.08M，占总股份比例：0.13%。
Brandes Investment Partners, L.P.持有股份：3.71M，占总股份比例：0.12%。
武田制药的前三大股东类型是什么？
武田制药 的前三大股东类型分别是：
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
有多少机构持有武田制药(TAK)的股份？
截至2025Q3，共有606家机构持有武田制药的股份，合计持有的股份价值约为78.67M，占公司总股份的2.49%。与2025Q2相比，机构持股有所增加，增幅为0.19%。
哪个业务部门对武田制药的收入贡献最大？
在FY2026Q1，Gastrointestinal diseases业务部门对武田制药的收入贡献最大，创收339.30B，占总收入的30.66%。
